



Innovating for
affordable healthcare

Shilpa Medicare Limited

Corporate & Admin Office :

"Shilpa House", # 12-6-214/A-1, Hyderabad Road,
Raichur-584 135, Karnataka, India

Tel: +91-8532-238704, Fax: +91-8532-238876

Email: info@vbsilpa.com, Web: www.vbsilpa.com

CIN: L85110KA1987PLC008739

Dated: 15th February, 2021

Corporate Relationship Department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai-400 001

National Stock Exchange of India
Limited
Exchange Plaza, 5th Floor,
Plot No.C/1, G Block
Bandra Kurla Complex, Bandra (E)
MUMBAI-400 051

Dear Sir/Madam,

Sub: Intimation U/R 30 of the SEBI(LODR) Regulations- Reg.

Ref: Stock Code: NSE: SHILPAMED/BSE-530549

Shilpa Medicare Limited Launches Sunitinib Capsules under the brand name SUNISHIL in India

Shilpa Medicare Ltd., a research-led global integrated pharmaceutical company, today announced launch of Sunitinib Capsules, under the brand name SUNISHIL. Three strengths of Sunitinib capsules 12.5 mg, 25 mg and 50 mg is launched at an attractive price for the benefit of patients.



Sunitinib malate is a novel oral multi targeted tyrosine kinase inhibitor with antitumor and antiangiogenic activities.

V.V. K. Choudhary



Innovating for
affordable healthcare

Shilpa Medicare Limited

Corporate & Admin Office :

"Shilpa House", # 12-6-214/A-1, Hyderabad Road,
Raichur-584 135, Karnataka, India

Tel: +91-8532-238704, Fax: +91-8532-238876

Email: info@vbshilpa.com, Web: www.vbshilpa.com

CIN: L85110KA1987PLC008739

Sunitinib Capsules are indicated for the treatment of G.I. Stromal tumor after disease progression on or intolerance to Imatinib mesylate, advanced Renal Cell Carcinoma, and for the treatment of Unresectable or Metastatic Well-differentiated Pancreatic Neuroendocrine Tumors with Disease Progression in Adults.

Shilpa's Sunitinib Capsules will be manufactured and supplied from state-of-the-art finished product facility at Jadcherala. SUNISHIL will be supplied as 12.5mg, 25mg and 50mg strengths and is available in a pack size of 28 capsules.

Shilpa's Sunitinib Capsules has proven to be bioequivalent to international brand SUTENT® capsules of Pfizer.

This is for your information and doing the needful.

With Regards,

For **SHILPA MEDICARE LIMITED**


V V KRISHNA CHAITANYA
Company Secretary and
Compliance officer

